In TEMSO, patients were randomized 1:1:1 to receive placebo, teriflunomide 7 mg or 14 mg for ≤108 weeks. BVL was assessed as annualized percentage brain volume change (PBVC) from baseline using SIENA at Years 1 and 2 in patients stratified by age: ≤25 years, >25 to ≤35 years, >35 to ≤45 years, and >45 years. Treatment group comparisons of median PBVC values were made via ranked ANCOVA, adjusted for region, age, Expanded Disability Status Scale strata, and baseline normalized brain volume at baseline. Data are presented at Year 2 for all patients treated with teriflunomide 14 mg vs. placebo, and for patients aged >45 years treated with teriflunomide 14 mg vs. placebo.

The median annualized PBVC in all patients was 30.6% lower in the teriflunomide 14 mg group (n=235) vs. placebo (n=234; P=0.0001). In patients >45 years, the median annualized PBVC was 35.0% lower in the teriflunomide 14 mg group (n=49) vs. placebo (n=48; P=0.0098).

 Teriflunomide decelerated disease-related brain atrophy in RMS patients vs. placebo in the total group, and in patients aged >45 years. The beneficial effect of teriflunomide on brain atrophy appears to persist across age groups.